Corpus Intelligence IC Memo — LUTHERAN HOSPITAL 2026-04-26 12:04 UTC
IC Memo — LUTHERAN HOSPITAL
Investment Committee Memorandum | OH | 110 beds | Grade C | EBITDA uplift $10.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LUTHERAN HOSPITAL

CCN 360087 | CUYAHOGA, OH | 110 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

LUTHERAN HOSPITAL is a 110-bed suburban community hospital in CUYAHOGA, OH with $140.0M in net patient revenue and a 3.4% operating margin. The hospital serves a payer mix of 14.7% Medicare, 6.1% Medicaid, and 79.2% commercial.

Thesis: Undervalued. Our ML models identify $10.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 3.4% to 10.7% (+736bps).

Net Revenue HCRIS$140.0M
Current EBITDA COMPUTED$4.7M
Operating Margin COMPUTED3.4%
Occupancy HCRIS32.7%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS32.2%
Distress Probability ML52.2%

2. Market Context & Competitive Position

235
OH Hospitals
-0.3%
State Median Margin
100
Comparable Hospitals

OH has 235 Medicare-certified hospitals with a median operating margin of -0.3%. The target's margin of 3.4% places it above the state median. Among 100 size-comparable peers (55-220 beds), the median margin is 1.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (55-220), prioritizing same-state peers. 100 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LUTHERAN HOSPITAL (Target)OH110$140.0M3.4%
DAYTON CHILDRENS HOSPITALOH181$569.1M7.9%
MARIETTA MEMORIAL HOSPITALOH188$475.8M-12.4%
ADENA REGIONAL MEDICAL CENTEROH209$470.7M3.5%
SOUTHERN OHIO MEDICAL CENTEROH192$424.3M-4.9%
SOUTHWEST GENERAL HEALTH CENTEOH191$406.9M2.5%
MARION GENERAL HOSPITALOH177$365.7M35.5%
DUBLIN METHODIST HOSPITALOH110$333.9M28.4%
JEWISH HOSPITAL OF CINCINNATIOH170$333.6M-5.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $10.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.9M+210bp18mo
Cost to Collect4.5%2.5%$2.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.7M+122bp9mo
Clean Claim Rate88.0%96.0%$90K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.9M
Cost to Collect
$2.8M
Denial Rate Reduction
$2.8M
A/R Days Reduction
$1.7M
Clean Claim Rate
$90K
Total EBITDA Uplift$10.3M
Current EBITDA$4.7M
+ RCM Uplift+$10.3M
Pro Forma EBITDA$15.0M
Current Margin3.4%
Pro Forma Margin10.7%
WC Released (1x)$5.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$7.3M$134.3M18.44x79.1%
Base (11x exit)10.0x11.0x$7.3M$150.1M20.61x83.1%
Bull Case9.0x11.0x$6.6M$186.5M28.44x95.3%
Bull (12x exit)9.0x12.0x$6.6M$205.4M31.32x99.2%
Bear Case11.0x10.0x$8.0M$80.4M10.03x58.6%
Bear (11x exit)11.0x11.0x$8.0M$91.0M11.36x62.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 32.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 52.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 100 hospitals with 55-220 beds
  • Same-state prioritization (n=101)
  • Comp margins: P25=-12.4% / P50=1.4% / P75=8.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.